Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash Flows From Operating Activities:
Net loss	$ (4,159,000)	$ (1,916,852)
Adjustments to reconcile net loss to cash used in operating activities
Amortization of debt discount		249,570
Accrued interest		59,869
Change in fair value of warrant derivatives	(6,272,543)
Stock-based compensation	4,342,498
Inducement expense	298,714
Amortization of intangible assets	310,659
Change in operating assets and liabilities
Prepaid expenses and other current assets	(190,757)	(52,116)
Accounts payable and other current liabilities	486,274	414,473
Net cash used in operating activities	(5,184,155)	(1,245,056)
Cash Flows From Investing Activities:
Purchase of Diverse Bio license agreement	(675,000)
Net cash used in investing activities	(675,000)
Cash Flows From Financing Activities:
Proceeds from sale of common stock and warrants, net of offering costs	21,614,488
Proceeds from convertible notes payable		50,000
Proceeds from note payable		1,812,410
Repayment of note payable		(157,714)
Proceeds from warrant exercises	3,285,173
Net cash provided by financing activities	24,899,661	1,704,696
Effect of foreign exchange rate on cash	(1,049)	(61,961)
Net increase in cash	19,039,457	397,679
Cash - Beginning of period	1,578,460	43,714
Cash - end of period	20,617,917	441,393
Supplemental non-cash financing activities:
Beneficial conversion feature issued with note payable		17,851
Warrants issued in conjunction with notes payable issuances		32,149
Shares of common stock issued for accounts payable		$ 173,482